Utah doctors are challenging the state’s AI plan for prescription refills, potentially deterring similar pilots and forcing AI companies to prove patient safety and gain physician support before launching experiments.
Millennials lead in online health purchases, but brands still need to compete with trusted reviews, active engagement, and clear value and convenience.
Waning consumer faith in traditional media and public health agencies means brands must turn to local doctors and creators to counter false health claims.
Close to 40% are familiar with the concept of healthspan and are actively building the foundation for healthier aging.
Regeneron caps Trump’s first deal wave with price cuts and US investment, but risks codifying federal pricing rules into law.
More physicians are using AI for clinical search, pushing tech companies to compete on speed, medical sourcing, and trust.
With insurers declining to participate in GLP-1 coverage, Medicare will now subsidize the drugs, though concerns around muscle loss may temper prescribing.
RFK Jr. backs voluntary limits for food marketing, aligning unhealthy food with pharma in Washington’s broader crackdown on health-linked marketing.
The anti-aging market isn’t fueled by broad, mass adoption. In reality, only about 10% of US consumers actively prioritize preventing signs of aging, according to YouGov’s 2026 Anti-aging report.
Amazon aims to turn GLP-1 demand into a funnel for One Medical, though limiting new prescriptions to members softens the competitive threat to other telehealth players.
By cutting unprofitable members to restore margins and investing in AI to boost efficiency, UnitedHealth’s strategy offers insurers a 2026 survival guide.
Many self-diagnosers skip seeing a provider—raising the stakes for pharma brands to better connect patients with doctors.
Its Kelonia acquisition, alongside neurology and immunology moves, makes a more sustainable drug pipeline beyond its blockbuster GLP-1s.
The drugs will get expedited FDA review and expanded patient access as soon as summertime amid rising consumer interest and clinician caution.
The $625 million raise signals Wall Street’s conviction in durable GLP-1 weight loss drug demand even as more players crowd the field.
Nearly half delay or skip doctor visits, turning to over-the-counter and at-home remedies to save money.
Health plans reduced prior authorizations by 11%, but pressure on insurers remains as the changes risk seeming cosmetic without clear impact on clinicians and patients.
Failing to obtain consent when using AI scribes during medical appointments breaches trust, damages reputations, and risks driving patients away.
Consumers are increasingly turning to AI to overcome cost and access barriers. But because its health advice can be unreliable, provider organizations should guide safe use and offer their own vetted chatbots.
As Medicare GLP-1 coverage begins, Walmart can capture more weight-care demand from its boomer customer base.